Paysign Reports Strong Q3 2026 Growth Driven by Patient Affordability Programs
Paysign (PAYS) delivered robust third-quarter 2026 results, characterized by a 42.6% year-over-year revenue increase to $30.8 million. The growth was primarily fueled by the company's patient affordability segment, which saw pharma revenue surge by nearly 110%. This shift in revenue mix led to significant margin expansion, with gross margins rising to 64.7% and net income increasing over 204% compared to the previous year. Despite the strong financial performance, management addressed a headwind regarding its plasma segment, noting that one customer will transition 113 centers to another provider in Q4. However, the company expects pharmaceutical service momentum to offset this loss. Paysign maintains a healthy balance sheet with $34.5 million in unrestricted cash and zero bank debt, while providing optimistic full-year guidance for revenue and adjusted EBITDA.
Topics: margin expansion net income increase patient affordability programs revenue growth
Read the full article at Motley Fool
Part of the story Endeavour Silver Reports Strong Q3 2026 Growth Driven by Higher Metal Prices (6 articles)